Controversial Gene Therapy Wins FDA Approval for Duchenne Muscular Dystrophy
(MedPage Today) -- The FDA granted accelerated approval to delandistrogene moxeparvovec (Elevidys), the first gene therapy for Duchenne muscular dystrophy, the agency announced Thursday.
The adeno-associated virus-based gene therapy is a one-time...
Source: MedPage Today Neurology - Category: Neurology Source Type: news
More News: Adenoviruses | Brain | Gene Therapy | Genetics | Muscular Dystrophy | Neurology | Reflex Sympathetic Dystrophy